Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should see TNBC detailed data from Phase I pilot study at AACR Annual Meeting 2018 April 14-18, 2018. Should hear news about partnering with BMY or MRK for Phase II TNBC trial which will be sponsored by Oncosec; and as they disclosed today....that was the reason for the latest 23 million equity raise. So moving forward TNBC is the next catalyst before PISCES data later this year.
According to the principal investigator, Alain Algazi, for the Oncosec/Merck combo study for anti-pd1 predicted failures, the 50% BORR reported at SITC should be replicated in PISCES trial. This means the data is going to rock big time!
Jeff, I'll take that cup and handle with my cup of coffee and relish in the breakout when it happens. We know it is coming soon.
Jeff, I didn't think you were being negative at all. ONCS has bee a tough stock to own over the years. It seems very manipulated just when you think it will break out, it gets crushed. This year is different though....all signs positive. Good luck fellow long. Good times ahead. Today looks like a nice move up coming.
Jeff, momentum and chart look solid. Now we just need some news to really get us moving higher.
I think Oncosec shares are holding up fairly well right now with last weeks turmoil in the market. Chart looks ready to move higher. GLTU too Ahab!
News drop at any time could have Oncosec shooting higher.
When you panic sell only to watch your stock rocket higher weeks and months later, it can really cause you mental health issues. Best to learn patience.....and wait out the bad times.....when the fundamentals are as solid as they are with an undervalued company like Oncosec.
Lots to look forward to with Oncosec this year. Fools will sell right now before major catalysts.
Jeff, I have a feeling we will see a 13G after hours today....and we will be back over $2 monday.
Definitely large positions being loaded. Catalysts this year holding us up in the overall uptrend. When the market bounces back Oncosec will run with news. Going higher soon. Not worried at all, it will happen.
The payoff with a huge risk is that there is the possibility for huge return. Right now the pullback in Oncosec shares with the overall market is giving investors the chance to buy at a discount...and I will be taking some more Oncosec shares at the open tomorrow from weak-handed traders.
PISCES trial will confirm the findings in the SITC data regardless of the small sample size. Based on two responders in the TNBC pilot study Oncosec will launch a combo-TNBC trial soon. Things are happening for this tiny company this year. PISCES is just the beginning.
The facts presented at SITC in November which I observed would contradict your assumption. 50% BORR in non-responder melanoma population is compelling data. PISCES data will confirm the results without a doubt in my mind.
Thanks for the savvy advice. I will sell my entire position in Oncosec right now so I can miss out on the rise in share price that takes place when they release positive interim PISCES data this year which will lead to either a licensing deal or buyout worth way more than the current share price. Thanks so much for the advice.
Short traders might be throwing the baby out with the bath water here. Simply a better buying opportunity. I have picked up some more shares. Anyone who is familiar longer term with the Oncosec story knows this could end the year much higher than the current share price, regardless of market conditions. All rests on PISCES data, which I think will be stellar.
Looking at the one year chart I would say there is strong support right around $1.50 and funny that is where the recent offering was priced at. I am confident the uptrend holds in time for solid positive news this year.
In the wake of a major market correction, Oncosec is about to complete a major equity offering and they will be well funded for the rest of 2018. Oncosec may just turn out to be a go-to stock that will rise while the rest of the market remains stagnant this year. Major catalyst with the PISCES data release later this year. Oncosec is up 6% today. Not the time to sell here.
Later this year we will find out just how capable this company is...when interim PISCES data is released. I'll check back with you then Dr. If the results are good, I expect the share price to be much higher then the current level.
They are immunotherapy companies, not tow campanies for your information. LOL!
Big Pharma should be shaking in their boots if Oncosec and Avacta are "looking to make current checkpoint inhibitors obsolete". Things are only going to get more interesting as this year progresses. I personally am on the edge of my seat right now. Very exciting time.
If Oncosec intends to start a TNBC phase II trial they will need money for that too. The IST's trials are at no cost to Oncosec. When they announce the collaboration for TNBC that should have the price moving back up easily.
According to Scottrade it is $24 mil Deal, 13,300,000 Deal Breakdown and closing date of 2/2 so this must be an institution right?... if a closing date is listed for tomorrow, dividing that $24 mil by that share amount gives you $1.81 per share I believe from yesterdays closing price. I think we will see a filing from a large Tute in a few days.
Relax Folks, looks like offering is for $24 mil, 13,300,000 mil shares, no warrants, looks like closing price of $1.81 today. If stock opens up lower tomorrow I think it will bounce back quickly. TNBC collaboration will most likely be with Bristol Myers and be like the Merck collaboration; so Oncosec will sponsor the trial and BMY provide the drug.....that is my take, they will need the money to get TNBC rolling as well as for PISCES trial. No more dilution this year until PISCES data. I also like that Piper Piper Jaffray and Cantor Fitzgerald are handling the offering....a step up in my opinion.
Oncosec may be trying to keep the advances on the gene delivery system low key until they actually advance a therapy into the clinic with Avacta. It looks and sounds like a great collaboration for the future.
looking at Avacta's website and their pipeline I think you are exactly right. Avacta quote: The company has initiated its first internal programme targeting PD-L1 inhibition in order to rapidly progress the first Affimer therapeutic to the clinic
From the pr today put out by Avacta:
"The collaboration between the companies aims to show that, by using ImmunoPulse to deliver DNA encoding Avacta's immuno-modulatory Affimers, including Avacta's PD-L1 inhibitor (AVA04), into tumor cells and other tissues, a clinically relevant dose can be achieved. The companies plan to then demonstrate efficacy of the Affimers in a relevant in vivo tumor model."
Definitely looks like some very positive synergy is going to happen between Oncosec and Avacta. I like it!
Oncosec's master plan begins to unfold in 2018!
This is the ace up Oncosec's sleeve. When they started the TAP program, the strategy was to get the technology into very capable hands such as Jounce and InhibRX, stir more interest in the technology and than later open up the potential for major licensing deals. Another great value driver in addition to the great potential of the PISCES trial and other indications and partnerships to come after results.
hschlauch, I have a question for you because you are the "science Man". InhibRX is a TAP collaborator with Oncosec and I noticed that they are licensing a mAb from Celgene in their clinical studies. Do you see the possibility of Celgene being a partner for Oncosec's multi-gene construct (PIIM)? This has been very hush hush and all other collaborators on Oncosec's website have been removed, but these collaborations obviously are ongoing since they were just recently mentioned in the 2018 outlook pr.
below is the link to inhibRX....appreciate any incites you might have about the possibility of a Celgene partnership. Most are just thinking Merck or Bristol Myers for anti-pd1.
http://inhibrx.com/therapeutic-areas/oncology/
Gargosky said the response in the two patients treated with Opdivo after ep-il12 was robust....so I would bet that Oncosec gets this into a fast track phase II trial same as PISCES....especially because the response rates in TNBC monotherapy are extremely low. This would probably get breakthrough status designation too.
Thanks Titan. I too am hoping the TNBC trial follows the same regulatory fast-track pathway as PISCES. Should also get orphan drug designation too.
Titan do you know of any upcoming conferences that Oncosec might announce the details of the TNBC data. Hopefully a conference happening soon to keep the momentum going.
Market trying to knock the price down at the open. Nice try. Going higher for sure on positive data.
Same can be said about the Head and Neck data which was enough to get another IST trial going (no cost to Oncosec). Data in Head and Neck I believe was only a few patients but again very encouraging results.
We won't know the details of the TNBC pilot study until a medical conference, but it must be very positive because they are already preparing a phase II combo study in TNBC because of this data. The results are with Opdivo on 2 patients....so obviously we will be in collaboration with Bristol Myers and I would say that is very Bullish.
I agree Jeff, and 2018 is going to be a very interesting year for Oncosec.
Oncosec technicals and fundamentals all point to...BULLISH!
I can tell you this my friend, Oncosec is going to be a $20 stock at least sooner or later...and that is no nonsense...that is a company coming of age and bringing forth innovation. Oncosec should be commended for the therapy they are advancing and saving lives along the way while they lay the groundwork for what will be a Golden Age in cancer immunotherapy in the next decade. PISCES data this year will mark the biggest milestone in their history....and it will be big...and well received by the market.
I agree that a BMY/Merck battle is going to be a real Smackdown!...of sorts. Only a few months ago Oncosec was saying how they were completely 100% focused on the PISCES trial and shutting down all other trials and locking down data. Now after the SITC data release in November which even Punit was surprised at the better than expected BORR numbers, we get a 2018 outlook laying out the initiation of multiple new trials and plans to move the Genesis technology to the next generation. Very Bold moves for 2018. I think Oncosec is positioning quickly to have as much bargaining fire power at the table when deals start coming in. In 2018...IT's ON!